Bone Medical Developing Potentially First Rheumatoid Arthritis Drug To Treat Both IL6 And TNF, Australia

New data from the Bone Medical Ltd (ASX: BNE) rheumatoid arthritis (RA) programme shows that its lead drug candidate BN006 is capable not only of down-regulating TNF secretion, but also of inhibiting secretion of IL6. BN006 has been developed as an inhibitor of secretion of TNF, one of the cytokines involved in the inflammatory process that perpetuates RA.

More: continued here

Filed under: Arthritis on January 29th, 2008